improving csf biomarkers’ performance for predicting progression from mild cognitive impairment to alzheimer’s disease: a meta-analysis

Clicks: 207
ID: 227307
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Background: CSF biomarkers’ performance for predicting conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD) is still suboptimal. Objective: By considering several confounding factors we aimed to identify in which situations these CSF biomarkers can be useful. Data sources: A systematic review was conducted on MEDLINE, PreMedline, EMBASE, PsycInfo, CINAHL, Cochrane, and CRD (1990-2013). Eligibility criteria: 1) prospective studies of CSF biomarkers’ performance for predicting conversion from MCI to AD/dementia; 2) inclusion of Aß42 and T-tau and/or p-tau. Several meta-analyses were performed. Results: Aß42/p-tau ratio had high capacity to predict conversion to AD in MCI patients younger than 70 years. P-tau had high capacity to identify MCI cases converting to AD in ≤24 months. Conclusions: Explaining how different confounding factors influence CSF biomarkers’ predictive performance is mandatory to elaborate a definitive map of situations where these CSF biomarkers are useful both in clinics and research.
Reference Key
eferreira2014frontiersimproving Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Daniel eFerreira;Amado eRivero-Santana;Lilisbeth ePerestelo-Perez;Eric eWestman;Lars-Olof eWahlund;Antonio eSarria-Santamera;Pedro Guillermo Serrano-Aguilar
Journal Frontiers in chemistry
Year 2014
DOI
10.3389/fnagi.2014.00287
URL
http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00287/full
Keywords
mild cognitive impairment meta-analysis systematic review alzheimer’s disease csf biomarkers neuropsychiatry biological psychiatry

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.